BIND, Pfizer ally to develop highly targeted Accurins therapies

04/4/2013 | Genetic Engineering & Biotechnology News

Pfizer and BIND Therapeutics agreed to collaborate in the development and marketing of Accurins, a new class of highly targeted and programmable treatments, using the latter's Medicinal Nanoengineering platform. The partners will jointly conduct preclinical research, and Pfizer has the right to develop and market the Accurins it chooses. BIND could get $50 million in upfront and development milestone fees from Pfizer. BIND is also eligible to receive around $160 million in regulatory and sales milestone fees for each Accurin that is commercialized, plus sales royalties.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC